Nordson (NDSN) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
11 Jan, 2026Executive summary
Achieved record sales of $2.7 billion and record EBITDA of $849 million (32% of sales) for fiscal 2024, driven by the Ascend Strategy, NBS Next Growth Framework, and successful integration of Atrion, despite challenging macro conditions.
Demonstrated strong cash flow generation and consistent performance, with free cash flow of $492 million and a 105% conversion rate.
Growth was supported by acquisitions, notably Atrion, and a high mix of recurring revenue, now at 57% of total sales.
Entered fiscal 2025 with a $580 million backlog and a conservative outlook due to macroeconomic uncertainties.
Financial highlights
Q4 sales were $744 million, up 4% year-over-year, with Q4 EBITDA at $241 million (32% of sales), up 6% year-over-year.
Full-year adjusted EPS was $9.73, down 1% from prior year due to higher interest costs from acquisitions; GAAP EPS was $8.11, down 4%.
Q4 adjusted EPS was $2.78, up 3% year-over-year; GAAP EPS was $2.12, down 5%.
Free cash flow for the year was $492 million, with a 105% conversion rate on net income.
Q4 gross margin improved by 110 basis points year-over-year to 54.1%; full-year gross margin was 55.2%.
Outlook and guidance
Fiscal 2025 sales expected to grow 2%-7% over 2024, with adjusted EPS guidance of $9.70–$10.50 (flat to up 8%).
Q1 2025 sales forecasted at $615–$655 million, with adjusted EPS of $1.95–$2.15.
Guidance assumes a -1.5% FX impact, no significant recovery in electronics/agriculture, and 6% growth from Atrion.
Effective tax rate expected at 19%-21%, capex at $50-$60 million, and interest expense at $90-$100 million.
Long-term (2025–2029) targets: 6–8% annual revenue growth, 10–12% adjusted EPS growth.
Latest events from Nordson
- Record sales and earnings, with raised guidance and strong growth in ATS and Asia Pacific.NDSN
Q1 202619 Feb 2026 - Strong growth, innovation, and cash flow support 6-8% annual revenue growth through 2029.NDSN
Investor presentation19 Feb 2026 - Q3 sales up 2% to $662M; Atrion acquisition expands medical segment; guidance raised.NDSN
Q3 202423 Jan 2026 - 2025–2029 targets 6%-8% revenue and 10%-12% EPS growth, driven by strategy and portfolio evolution.NDSN
Investor Day 202420 Jan 2026 - Shareholders will vote on directors, auditor ratification, and executive pay amid record results and strong governance.NDSN
Proxy Filing16 Jan 2026 - Annual meeting to elect directors, ratify auditor, and approve executive pay, all board-recommended.NDSN
Proxy Filing16 Jan 2026 - Sales fell 2.8% but backlog surged 15%, signaling growth potential for 2025.NDSN
Q1 20258 Jan 2026 - Record sales, strong margins, and robust cash flow set up for solid growth in 2026.NDSN
Q4 202512 Dec 2025 - Record financials, strong governance, and key votes headline the 2025 proxy.NDSN
Proxy Filing1 Dec 2025